• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2012 Product Image

Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2012

  • ID: 2114464
  • April 2012
  • 104 pages
  • Global Markets Direct

Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2012', provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma. 'Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuro READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuro Endocrine (Carcinoid) Carcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Neuro Endocrine (Carcinoid) Carcinoma
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics under Development by Companies
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Products under Development by Companies
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Neuro Endocrine (Carcinoid) Carcinoma Therapeutics Development
F. Hoffmann-La Roche Ltd.
Novartis AG
Molecular Insight Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Camurus AB
Cylene Pharmaceuticals, Inc.
Neuro Endocrine (Carcinoid) Carcinoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Signifor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX1032 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onalta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOM230 + RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Interferon Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 706 + Octreotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quarfloxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 479 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FOLFOX + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viracept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DOTA-TOC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FOLFIRI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 + Octreotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octreotide + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pemetrexed - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW786034 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octreotide + Yttrium Y 90 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Temozolomide + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Irinotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
I-131 Metaiodobenzylguanidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Octreotide LAR + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon alfa + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-A12 + Octreotide + Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + 5-fluorouracil + Leucovorin + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + recombinant interferon alfa-2b + octreotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMF Regimen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus + Octreotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus + Octreotide + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panzem + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lutate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAM2029 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sandostatin LAR + RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 + Erlotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Drug Profile Updates
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Discontinued Products
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics - Dormant Products
Neuro Endocrine (Carcinoid) Carcinoma – Product Development Milestones
Featured News & Press Releases
Mar 20, 2012: Lexicon's Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment
Oct 22, 2011: Lexicon To Present Data From Phase II Clinical Studies Of Telotristat Etiprate At NANETS In Minneapolis, US
Aug 09, 2011: Lexicon Announces Positive Results From Phase II Trial Of Telotristat Etiprate In Carcinoid Syndrome
Dec 16, 2010: Advanced Accelerator Applications Receives GMP Approval To Manufacture Lutate For Treatment Of Neuroendocrine Tumors
Dec 02, 2010: Pfizer Receives European Approval For SUTENT For New Indication In Progressive Pancreatic Neuroendocrine Tumors
Oct 11, 2010: Phase III Novartis Data Show Potential Benefit Of Afinitor Plus Sandostatin LAR In Patients With Advanced Neuroendocrine Tumors
Apr 12, 2010: Affinium Begins Phase I Clinical Trial Using Optimized Oral Formulation Of AFN-1252
Apr 12, 2010: Molecular Insight's Onalta Phase II Data Published In Journal Of Clinical Oncology
Jul 21, 2009: LX1032 Receives Orphan Drug Designation From EMEA For Carcinoid Syndrome
Jul 08, 2009: LX1032 Phase 2 Clinical Trial Initiated By Lexicon In Patients With Carcinoid Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Neuro Endocrine (Carcinoid) Carcinoma, H1 2012
Products under Development for Neuro Endocrine (Carcinoid) Carcinoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Novartis AG, H1 2012
Molecular Insight Pharmaceuticals, Inc., H1 2012
Lexicon Pharmaceuticals, Inc., H1 2012
Camurus AB, H1 2012
Cylene Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Drug Profile Updates
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Discontinued Products
Neuro Endocrine (Carcinoid) Carcinoma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Neuro Endocrine (Carcinoid) Carcinoma, H1 2012
Products under Development for Neuro Endocrine (Carcinoid) Carcinoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos